FDA Approves Lilly’s Once-Weekly Insulin Onswik, Challenging Novo’s Awiqli
FDA clears Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It may cut 300+ shots a year and now competes with Novo’s Awiqli.
/ 107 items
#NVO↓
VKTX Jumps After Viking Shows Monthly and Every-Other-Week Shots Can Hold Most Weight Loss
Viking reported 16–19% weight loss at week 21 and strong maintenance on monthly dosing. GI side effects in the later phase looked like placebo.
Novo Shares Slide as Long-Term Goals Disappoint Market
Distant 2030 goals failed to ease concerns over patents and Lilly.
Novo: EU backing for new haemophilia treatment plus $1.4bn oral-drug pact
CHMP recommends FREHEMGO (denecimig) for haemophilia A, with or without inhibitors. Novo and Orbis will develop oral cardiometabolic drugs.
Ascendis Pharma Stock Drops After Ending Novo Partnership
Ascendis will develop TransCon obesity and cardiometabolic programs itself after ending its Novo collaboration and starting a $400M buyback.
Berenberg Sees 25% Upside in Eli Lilly as Obesity Drugs Keep Winning
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.